The article “Synergistic Protection of a general Caspase Inhibitor and MK-801 in Bilirubin-Induced Cell Death in Human NT2-N neurons”, by Erik Hankø, et al. (Pediatr Res 59:72–77) contained errors. Re-calculations did not change the principal conclusions, but the following errors are corrected:

In the abstract, the paragraph “zVAD.FMK (100 μM only) reduced …. differences after 48 h” should read: “zVAD.FMK enhanced neuronal survival by reducing apoptotic nuclear fragmentation, while MK-801 enhanced survival by reducing apoptotic nuclear condensation; both without affecting the MTT assays. Combined treatment reduced both apoptotic morphologies (without affecting necrosis), and this effect was also reflected in the MTT assays.”

Page 74, left column, second paragraph, the sentence beginning “The two different caspases” should read: “zVAD.FMK significantly enhanced neuronal survival, while zDEVD.FMK had no such effect.”

Page 74, left column, second paragraph, the sentence beginning “Both caspase inhibitors” should read: “zDEVD.FMK significantly enhanced the proportion of condensed nuclei (after 24 h).”

Page 74, right column, second paragraph, the sentence beginning “MK-801 significantly reduced” should read: “MK-801 enhanced the proportion of undamaged nuclei at 48 h, but did not significantly enhance MTT reduction.”

The authors regret the errors. A set of corrected figures is available in PDF format from Erikh@ulrik.uio.no.